đź’¨ Abstract

AC Immune SA, a Swiss biopharmaceutical company, reported a loss of $21.2 million and 21 cents per share in Q1 2025, with revenue of $1.1 million. The company's shares closed at $1.70, down from $2.40 a year ago. This news was generated by Automated Insights using data from Zacks Investment Research.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖

Powered by MessengerX.io